Oryzon to Present at the Sachs Associates 2nd Annual Neuroscience BioPartnering & Investment Forum

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Dr. Carlos Buesa, Oryzon’s Chief Executive Officer, is scheduled to present at the SACHS Associates 2nd Annual Neuroscience BioPartnering & Investment Forum, being held March 27, 2017 at the New York Academy of Sciences in New York City.

 

Click here to see the full Press Release